Stephen B. Gauld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stephen B. Gauld has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Joseph B. Wetter
Dermatology, AbbVie Inc, North Chicago, Illinois, USA
3 shared publications - Yibing Wang
Dermatology Discovery AbbVie Inc. North Chicago Illinois USA
3 shared publications - Donna Gauvin
Dermatology, AbbVie Inc, North Chicago, Illinois, USA
2 shared publications - Jessica De Santis
Pediatrics, Medical College of Wisconsin , Milwaukee, WI
2 shared publications Laura Leys
AbbVie Inc., North Chicago, Illinois (S.B.G., Y.W., L.L., S.H., Z.S., J.W., K.S., S.P.M., P.H., K.D., M.E.K., D.G., R.E.); Inventiva, Daix, France (J.-M.L., D.B., D.P., P.J.M., S.J.); and AbbVie Bioresearch Center, Worcester, Massachusetts (C.W., R.M., C.G., M.A.A., E.B., K.C.).
2 shared publications- Prisca Honore
AbbVie Inc North Chicago IL USA
2 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1744273
Editorial: Exploring immune-stromal cell dynamics: pathways and therapeutic implications
Yasmin et al. provided a comprehensive review on the architectural and functional diversity of stromal subsets in secondary lymphoid organs. The authors summarize key findings on the heterogeneous molecular phenotypes of distinct stromal populations such as fibroblastic reticular cells (FRCs), follicular dendritic cells (FDCs), marginal reticular cells, and adventitial cells in lymph nodes, spleen, and Peyer's patches. These subsets occupy discrete anatomical niches throughout secondary lymphoid organs and provide scaffolding critical for immune cell migration, antigen presentation, germinal center (GC) formation and orchestration of adaptive responses. Notably, fibroblasts are emerging as immune sentinels that express patternrecognition receptors, shape cytokine and chemokine milieus, and regulate central and peripheral tolerance. For example, fibroblast subsets and FDCs modulate germinal center formation, supporting various aspects of B cell development and antibody responses. During infection or inflammation, fibroblast subsets in SLOs respond by remodeling the extracellular matrix (ECM), upregulating inflammatory mediators and modulating the activation threshold of T cells.Advancements in omics platforms and integrative data analyses of disease samples and preclinical models continue to elucidate the role of immune-stromal interactions in shaping pathogenic microenvironment during disease. To this end, Liu et al. utilized single-cell RNA sequencing to provide an in-depth atlas of cell populations within abdominal aortic aneurysm (AAA) using a classical preclinical mouse model. The study detected fibroblast subtypes with inflammatory and distinct metabolic phenotypes unique to AAA, expressing Apoc1/Fabp4 (lipid metabolism) and various immune activating factors such as CCL, TGFβ, and TNF. Pseudotime and trajectory analyses, along with cell-cell interactome analyses suggested that fibroblasts play a crucial role in driving the Trem2-positive macrophage population, a dominant inflammatory effector cell type that may perpetuate vessel wall injury and aneurysm progression.Under pathogenic conditions such as chronic inflammation, mesenchymal cells can be derived from epithelial origin through epithelial-mesenchymal transition (EMT). Zhang et al. summarizes the field of EMT as a key pathophysiological process underlying irreparable airway remodeling in asthma. Chronic allergic inflammation, eosinophil infiltration, and repetitive epithelial injury activate EMT via TGF-β, Wnt, Notch, and MAPK signaling cascades. This leads to the loss of epithelial integrity, enhanced generation of migratory fibroblast and myofibroblast, and accumulation of extracellular matrix, perpetuating fixed airflow obstruction. Additional mechanisms such as microRNA regulation and autophagy affect EMT, airway remolding and fibrogenesis. Although knowledge gaps remain -including exact triggers, genetic/epigenetic regulation and reversibility of EMT -this study highlights the therapeutic potential of EMT related pathways for asthma, addressing airway remodeling and fibrosis.The unique and pleiotropic ability of stromal cells to regulate inflammatory, fibrosis, and wound repair pathways underscores their therapeutic potential in various diseases via multipronged mechanisms of action. Hazrati et al. provide a seminal review of mesenchymal stem cell (MSC)-based therapies for a spectrum of lung diseases, including COPD, asthma, idiopathic pulmonary fibrosis (IPF), and viral infections. In contrast to traditional anti-inflammatory drugs, which often fail to restore immune homeostasis or regenerate lost tissue, MSCs -through secretion of cytokines, growth factors and exosomes -can drive robust immunomodulation, tissue regeneration, and reversal of fibrosis. Preclinical studies have demonstrated the ability of MSCs to dampen pathological neutrophil and Th17 responses, enhance Treg function, and skew macrophages toward a reparative M2 phenotype. Despite remaining challenges such as ensuring targeted MSC migration, refining exosome engineering, and evaluating long-term safety in chronic diseases, the pleiotropic effects underscore the promise of MSC therapies in delivering transformative therapies for lung diseases.Collectively, this research topic highlights a paradigm shift: mesenchymal and stromal cells are dynamic regulators, not mere structural bystanders, in both tissue homeostasis and immune dysfunction. Advanced molecular and single-cell analyses now enable precise mapping of cell heterogeneity and interactions, supporting the design of novel immunomodulatory and antifibrotic interventions. Future progress in treating chronic inflammation, fibrosis, and immune dysregulation across various diseases will increasingly depend on our ability to understand and therapeutically manipulate the mesenchymal and stromal landscape.
- 15 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1744273
Open AccessEditorial: Exploring immune-stromal cell dynamics: pathways and therapeutic implications
Yasmin et al. provided a comprehensive review on the architectural and functional diversity of stromal subsets in secondary lymphoid organs. The authors summarize key findings on the heterogeneous molecular phenotypes of distinct stromal populations such as fibroblastic reticular cells (FRCs), follicular dendritic cells (FDCs), marginal reticular cells, and adventitial cells in lymph nodes, spleen, and Peyer's patches. These subsets occupy discrete anatomical niches throughout secondary lymphoid organs and provide scaffolding critical for immune cell migration, antigen presentation, germinal center (GC) formation and orchestration of adaptive responses. Notably, fibroblasts are emerging as immune sentinels that express patternrecognition receptors, shape cytokine and chemokine milieus, and regulate central and peripheral tolerance. For example, fibroblast subsets and FDCs modulate germinal center formation, supporting various aspects of B cell development and antibody responses. During infection or inflammation, fibroblast subsets in SLOs respond by remodeling the extracellular matrix (ECM), upregulating inflammatory mediators and modulating the activation threshold of T cells.Advancements in omics platforms and integrative data analyses of disease samples and preclinical models continue to elucidate the role of immune-stromal interactions in shaping pathogenic microenvironment during disease. To this end, Liu et al. utilized single-cell RNA sequencing to provide an in-depth atlas of cell populations within abdominal aortic aneurysm (AAA) using a classical preclinical mouse model. The study detected fibroblast subtypes with inflammatory and distinct metabolic phenotypes unique to AAA, expressing Apoc1/Fabp4 (lipid metabolism) and various immune activating factors such as CCL, TGFβ, and TNF. Pseudotime and trajectory analyses, along with cell-cell interactome analyses suggested that fibroblasts play a crucial role in driving the Trem2-positive macrophage population, a dominant inflammatory effector cell type that may perpetuate vessel wall injury and aneurysm progression.Under pathogenic conditions such as chronic inflammation, mesenchymal cells can be derived from epithelial origin through epithelial-mesenchymal transition (EMT). Zhang et al. summarizes the field of EMT as a key pathophysiological process underlying irreparable airway remodeling in asthma. Chronic allergic inflammation, eosinophil infiltration, and repetitive epithelial injury activate EMT via TGF-β, Wnt, Notch, and MAPK signaling cascades. This leads to the loss of epithelial integrity, enhanced generation of migratory fibroblast and myofibroblast, and accumulation of extracellular matrix, perpetuating fixed airflow obstruction. Additional mechanisms such as microRNA regulation and autophagy affect EMT, airway remolding and fibrogenesis. Although knowledge gaps remain -including exact triggers, genetic/epigenetic regulation and reversibility of EMT -this study highlights the therapeutic potential of EMT related pathways for asthma, addressing airway remodeling and fibrosis.The unique and pleiotropic ability of stromal cells to regulate inflammatory, fibrosis, and wound repair pathways underscores their therapeutic potential in various diseases via multipronged mechanisms of action. Hazrati et al. provide a seminal review of mesenchymal stem cell (MSC)-based therapies for a spectrum of lung diseases, including COPD, asthma, idiopathic pulmonary fibrosis (IPF), and viral infections. In contrast to traditional anti-inflammatory drugs, which often fail to restore immune homeostasis or regenerate lost tissue, MSCs -through secretion of cytokines, growth factors and exosomes -can drive robust immunomodulation, tissue regeneration, and reversal of fibrosis. Preclinical studies have demonstrated the ability of MSCs to dampen pathological neutrophil and Th17 responses, enhance Treg function, and skew macrophages toward a reparative M2 phenotype. Despite remaining challenges such as ensuring targeted MSC migration, refining exosome engineering, and evaluating long-term safety in chronic diseases, the pleiotropic effects underscore the promise of MSC therapies in delivering transformative therapies for lung diseases.Collectively, this research topic highlights a paradigm shift: mesenchymal and stromal cells are dynamic regulators, not mere structural bystanders, in both tissue homeostasis and immune dysfunction. Advanced molecular and single-cell analyses now enable precise mapping of cell heterogeneity and interactions, supporting the design of novel immunomodulatory and antifibrotic interventions. Future progress in treating chronic inflammation, fibrosis, and immune dysregulation across various diseases will increasingly depend on our ability to understand and therapeutically manipulate the mesenchymal and stromal landscape.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (78) , eabq6691
Epiregulin is a dendritic cell–derived EGFR ligand that maintains skin and lung fibrosis
Immune cells are fundamental regulators of extracellular matrix (ECM) production by fibroblasts and have important roles in determining extent of fibrosis in response to inflammation. Although much is known about fibroblast signaling in fibrosis, the molecular signals between immune cells and fibroblasts that drive its persistence are poorly understood. We therefore analyzed skin and lung samples of patients with diffuse cutaneous systemic sclerosis, an autoimmune disease that causes debilitating fibrosis of the skin and internal organs. Here, we define a critical role of epiregulin-EGFR signaling between dendritic cells and fibroblasts to maintain elevated ECM production and accumulation in fibrotic tissue. We found that epiregulin expression marks an inducible state of DC3 dendritic cells triggered by type I interferon and that DC3-derived epiregulin activates EGFR on fibroblasts, driving a positive feedback loop through NOTCH signaling. In mouse models of skin and lung fibrosis, epiregulin was essential for persistence of fibrosis in both tissues, which could be abrogated by epiregulin genetic deficiency or a neutralizing antibody. Therapeutic administration of epiregulin antibody reversed fibrosis in patient skin and lung explants, identifying it as a previously unexplored biologic drug target. Our findings reveal epiregulin as a crucial immune signal that maintains skin and lung fibrosis in multiple diseases and represents a promising antifibrotic target.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (78) , eabq6691
Epiregulin is a dendritic cell–derived EGFR ligand that maintains skin and lung fibrosis
Immune cells are fundamental regulators of extracellular matrix (ECM) production by fibroblasts and have important roles in determining extent of fibrosis in response to inflammation. Although much is known about fibroblast signaling in fibrosis, the molecular signals between immune cells and fibroblasts that drive its persistence are poorly understood. We therefore analyzed skin and lung samples of patients with diffuse cutaneous systemic sclerosis, an autoimmune disease that causes debilitating fibrosis of the skin and internal organs. Here, we define a critical role of epiregulin-EGFR signaling between dendritic cells and fibroblasts to maintain elevated ECM production and accumulation in fibrotic tissue. We found that epiregulin expression marks an inducible state of DC3 dendritic cells triggered by type I interferon and that DC3-derived epiregulin activates EGFR on fibroblasts, driving a positive feedback loop through NOTCH signaling. In mouse models of skin and lung fibrosis, epiregulin was essential for persistence of fibrosis in both tissues, which could be abrogated by epiregulin genetic deficiency or a neutralizing antibody. Therapeutic administration of epiregulin antibody reversed fibrosis in patient skin and lung explants, identifying it as a previously unexplored biologic drug target. Our findings reveal epiregulin as a crucial immune signal that maintains skin and lung fibrosis in multiple diseases and represents a promising antifibrotic target.
- 1 July 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (7) , 1772-1779.e6
ACT1 Is Required for Murine IL-23–Induced Psoriasiform Inflammation Potentially Independent of E3 Ligase Activity
- 1 July 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (7) , 1772-1779.e6
ACT1 Is Required for Murine IL-23–Induced Psoriasiform Inflammation Potentially Independent of E3 Ligase Activity
- 1 October 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 371 (1) , 208-218
Inhibition of Interleukin-23–Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORγt
Blockade of interleukin (IL)-23 or IL-17 with biologics is clinically validated as a treatment of psoriasis. However, the clinical impact of targeting other nodes within the IL-23/IL-17 pathway, especially with small molecules, is less defined. We report on a novel small molecule inverse agonist of retinoid acid-related orphan receptor (ROR) γt and its efficacy in preclinical models of psoriasis and arthritis. 1-(2,4-Dichloro-3-((1,4-dimethyl-6-(trifluoromethyl)-1H-indol-2-yl)methyl)benzoyl)piperidine-4-carboxylic acid (A-9758) was optimized from material identified from a high-throughput screening campaign. A-9758 is selective for RORγt and exhibits robust potency against IL-17A release both in vitro and in vivo. In vivo, we also show that IL-23 is sufficient to drive the accumulation of RORγt+ cells, and inhibition of RORγt significantly attenuates IL-23-driven psoriasiform dermatitis. Therapeutic treatment with A-9758 (i.e., delivered during active disease) was also effective in blocking skin and joint inflammation. Finally, A-9758 exhibited efficacy in an ex vivo human whole blood assay, suggesting small molecule inverse agonists of RORγt could be efficacious in human IL-17-related diseases. SIGNIFICANCE STATEMENT: Using a novel small molecule inverse agonist, and preclinical assays, we show that RORγt is a viable target for the inhibition of RORγt/Th17-driven diseases such as psoriasis. Preclinical models of psoriasis show that inhibition of RORγt blocks both the accumulation and effector function of IL-17-producing T cells.
- 1 October 2019
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 371 (1) , 208-218
Inhibition of Interleukin-23–Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORγt
Blockade of interleukin (IL)-23 or IL-17 with biologics is clinically validated as a treatment of psoriasis. However, the clinical impact of targeting other nodes within the IL-23/IL-17 pathway, especially with small molecules, is less defined. We report on a novel small molecule inverse agonist of retinoid acid-related orphan receptor (ROR) γt and its efficacy in preclinical models of psoriasis and arthritis. 1-(2,4-Dichloro-3-((1,4-dimethyl-6-(trifluoromethyl)-1H-indol-2-yl)methyl)benzoyl)piperidine-4-carboxylic acid (A-9758) was optimized from material identified from a high-throughput screening campaign. A-9758 is selective for RORγt and exhibits robust potency against IL-17A release both in vitro and in vivo. In vivo, we also show that IL-23 is sufficient to drive the accumulation of RORγt+ cells, and inhibition of RORγt significantly attenuates IL-23-driven psoriasiform dermatitis. Therapeutic treatment with A-9758 (i.e., delivered during active disease) was also effective in blocking skin and joint inflammation. Finally, A-9758 exhibited efficacy in an ex vivo human whole blood assay, suggesting small molecule inverse agonists of RORγt could be efficacious in human IL-17-related diseases. SIGNIFICANCE STATEMENT: Using a novel small molecule inverse agonist, and preclinical assays, we show that RORγt is a viable target for the inhibition of RORγt/Th17-driven diseases such as psoriasis. Preclinical models of psoriasis show that inhibition of RORγt blocks both the accumulation and effector function of IL-17-producing T cells.
- Open Access
- 1 October 2018
- Published by Elsevier in Journal of Dermatological Science
- Vol. 92 (1) , 45-53
Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery
- 1 October 2018
- Published by Elsevier in Journal of Dermatological Science
- Vol. 92 (1) , 45-53
Open AccessMechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery
- 1 May 2016
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 136 (5) , S94
534 Defining a mechanistic link between TRPV3 activity and psoriasis through IL-1α and EGFR signaling pathways
- 1 May 2016
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 136 (5) , S94
534 Defining a mechanistic link between TRPV3 activity and psoriasis through IL-1α and EGFR signaling pathways
- Open Access
- 1 May 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 190 (Supplement) , 133.9
Regulation of pathogenic GL7-expressing helper T cells by Tregs and CD137 (P4111)
Dissecting the mechanisms that support autoantibody production is essential to our understanding of autoimmune diseases such as lupus. Recent work from our laboratory has shown that regulatory T cells (Tregs) play a key role in suppressing autoantibody production by helping to maintain B cell anergy. Our long-term goal is to understand how Tregs regulate B cell anergy. Our studies indicate that helper T cells play a key role as an intermediate between Treg and anergic B cells. Specifically, the absence of Tregs rapidly (within 4 days) drives the expansion of CD4+GL7+ helper T cells. This gross population can be further divided into 2 populations: germinal center follicular T cells (GC-TFH) and a novel non-TFH subset termed TAN cells. These GL7+ helper T cell subsets deliver potent signals to naïve and anergic B cells, inducing significant antibody production from both populations. Recent studies have begun to identify the signals that drive the expansion of GC-TFH and TAN cells in the absence of Tregs. We have shown that treatment of Treg-deficient mice with an agonistic anti-CD137 antibody reduces the expansion of CD4+GL7+ helper T cells (both GC-TFH and TAN cells). This treatment also reduced the expansion of class-switched B cells and abolished autoantibody production. Collectively, our studies indicate that CD137 signaling plays a key role in the expansion of pathogenic helper T cell subsets that support autoimmunity in the absence of Tregs.
- 1 May 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 190 (Supplement) , 133.9
Open AccessRegulation of pathogenic GL7-expressing helper T cells by Tregs and CD137 (P4111)
Dissecting the mechanisms that support autoantibody production is essential to our understanding of autoimmune diseases such as lupus. Recent work from our laboratory has shown that regulatory T cells (Tregs) play a key role in suppressing autoantibody production by helping to maintain B cell anergy. Our long-term goal is to understand how Tregs regulate B cell anergy. Our studies indicate that helper T cells play a key role as an intermediate between Treg and anergic B cells. Specifically, the absence of Tregs rapidly (within 4 days) drives the expansion of CD4+GL7+ helper T cells. This gross population can be further divided into 2 populations: germinal center follicular T cells (GC-TFH) and a novel non-TFH subset termed TAN cells. These GL7+ helper T cell subsets deliver potent signals to naïve and anergic B cells, inducing significant antibody production from both populations. Recent studies have begun to identify the signals that drive the expansion of GC-TFH and TAN cells in the absence of Tregs. We have shown that treatment of Treg-deficient mice with an agonistic anti-CD137 antibody reduces the expansion of CD4+GL7+ helper T cells (both GC-TFH and TAN cells). This treatment also reduced the expansion of class-switched B cells and abolished autoantibody production. Collectively, our studies indicate that CD137 signaling plays a key role in the expansion of pathogenic helper T cell subsets that support autoimmunity in the absence of Tregs.
- Open Access
- 1 April 2011
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (1_Suppleme) , 115.6
Role of helper T cells in the loss of B cell anergy mediated by the absence of Tregs (115.6)
Regulatory T cells (Tregs) are crucial for the maintenance of immune tolerance and the absence of Tregs results in significant autoantibody production. This suggests that Tregs play a key role in B cell tolerance. The mechanism by which Tregs regulate B cell tolerance has yet to be resolved but has important implications for our understanding of autoimmunity. Using both constitutive and inducible models, we show that the absence of Tregs results in autoantibody production, due to the loss of B cell anergy. Further studies show that this is dependent on the presence of helper T cells. We propose that the absence of Tregs results in the dysregulation of helper T cells that drive the loss of B cell anergy. Interestingly, our studies show the expansion of a CD4+GL7+ population in the absence of Tregs. Subsequent analysis shows that many of these cells express CXCR5 and thus resemble germinal-center TFH cells, an observation confirmed by their expression of Bcl6 and IL-21. We hypothesize that the absence of Tregs drives the expansion of TFH cells that play a role in the loss of B cell anergy. Characterization of this proposed mechanism may unveil new strategies for the treatment or prevention of autoantibody-mediated autoimmune diseases.
- 1 April 2011
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (1_Suppleme) , 115.6
Open AccessRole of helper T cells in the loss of B cell anergy mediated by the absence of Tregs (115.6)
Regulatory T cells (Tregs) are crucial for the maintenance of immune tolerance and the absence of Tregs results in significant autoantibody production. This suggests that Tregs play a key role in B cell tolerance. The mechanism by which Tregs regulate B cell tolerance has yet to be resolved but has important implications for our understanding of autoimmunity. Using both constitutive and inducible models, we show that the absence of Tregs results in autoantibody production, due to the loss of B cell anergy. Further studies show that this is dependent on the presence of helper T cells. We propose that the absence of Tregs results in the dysregulation of helper T cells that drive the loss of B cell anergy. Interestingly, our studies show the expansion of a CD4+GL7+ population in the absence of Tregs. Subsequent analysis shows that many of these cells express CXCR5 and thus resemble germinal-center TFH cells, an observation confirmed by their expression of Bcl6 and IL-21. We hypothesize that the absence of Tregs drives the expansion of TFH cells that play a role in the loss of B cell anergy. Characterization of this proposed mechanism may unveil new strategies for the treatment or prevention of autoantibody-mediated autoimmune diseases.